<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16595">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01849809</url>
  </required_header>
  <id_info>
    <org_study_id>IRB#2010-001</org_study_id>
    <nct_id>NCT01849809</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of Gamma Capsulotomy in Intractable OCD</brief_title>
  <official_title>Safety and Effectiveness of Gamma Capsulotomy in Intractable Obsessive Compulsive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Butler Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Butler Hospital</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A research study of the effectiveness and safety of gamma knife ventral capsulotomy in
      patients with severe intractable obsessive-compulsive disorder (OCD).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 1993</start_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Yale-Brown Obsessive Compulsive Severity Scale</measure>
    <time_frame>Change from baseline to 1 month, 6 months, 1 year, and then every year up to 30 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Obsessive Compulsive Disorder</condition>
  <arm_group>
    <arm_group_label>Gamma Ventral Capsulotomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Gamma Ventral Capsulotomy</intervention_name>
    <arm_group_label>Gamma Ventral Capsulotomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. OCD, diagnosed by Structured Clinical Interview for DSM-IV (SCID-IV), judged of
             disabling severity with a Yale-Brown Obsessive Compulsive Scale (YBOCS) score of at
             least 30 and a Social and Occupational Functioning Assessment Scale (SOFAS) score of
             45 or less.

          2. Persistence of severe symptoms and impairment for five or more years despite: 1. at
             least three adequate (≥3 months at the maximum tolerated dose) serotonin transporter
             inhibitor trials (fluoxetine, sertraline, fluvoxamine, paroxetine, citalopram,
             escitalopram, or clomipramine) alone or in combination with, 2. adequate behavior
             therapy (≥20 sessions of expert exposure and response prevention), and 3.
             augmentation of one of the selective SRIs with clomipramine, a neuroleptic, and
             clonazepam.

          3. Age between 18 and 65 years.

          4. Able to understand and comply with instructions.

          5. Able to give fully informed, written consent in the judgment of the Consent Monitor.

          6. Either drug free or on a stable drug regimen for at least 6 weeks.

          7. Good general health.

          8. A family member or significant other, in contact with the patient every 1-3 days, is
             available and willing to communicate with the research team if the patient's clinical
             status worsens.

          9. The local referring psychiatrist  is willing to provide ongoing care for the duration
             of the trial.

        Exclusion Criteria:

          1. Current or past psychotic disorder.

          2. Full-scale IQ below 85 on the Wechsler Abbreviated Scale of Intelligence (WASI),

          3. A clinical history of bipolar mood disorder.

          4. Any current clinically significant neurological disorder or medical illness affecting
             brain function, other than tic disorders or Tourette syndrome.

          5. Any clinically significant abnormality on preoperative magnetic resonance imaging
             (MRI).

          6. Inability to undergo presurgical MRI (cardiac pacemaker, pregnancy, metal in body,
             severe claustrophobia.

          7. Current or unstably remitted substance abuse, dependence, or a positive urine
             toxicology screen.

          8. Pregnancy and women of childbearing age not using effective contraception.

          9. Unable to adhere to operational and administrative study requirements (in the
             investigators' judgment).

         10. Clinical history of severe personality disorder.

         11. Imminent risk of suicide (in the investigators' judgment).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Rasmussen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Butler Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Butler Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 6, 2013</lastchanged_date>
  <firstreceived_date>February 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Butler Hospital</investigator_affiliation>
    <investigator_full_name>Steven Rasmussen</investigator_full_name>
    <investigator_title>Medical Director, Butler Hospital</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Obsessive-Compulsive Disorder</mesh_term>
    <mesh_term>Compulsive Personality Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
